

US006624193B1

(12) United States Patent

Naka et al.

(10) Patent No.: US 6,624,193 B1

(45) **Date of Patent:** Sep. 23, 2003

(54) PREVENTIVE AND THERAPEUTIC AGENTS FOR EYE DISEASES

(75) Inventors: **Hiroaki Naka**, Kobe (JP); **Kazuhito Kawabata**, Mishima-gun (JP); **Hideki**

Tokushige, Kobe (JP)

(73) Assignees: Ono Pharmaceutical Co., Ltd., Osaka

(JP); Senju Pharmaceutical Co., Ltd.,

Osaka (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

(21) Appl. No.: 10/070,307

(22) PCT Filed: Sep. 5, 2000

(86) PCT No.: PCT/JP00/06014

§ 371 (c)(1),

(2), (4) Date: Apr. 2, 2002

(87) PCT Pub. No.: WO01/17527

PCT Pub. Date: Mar. 15, 2001

(30) Foreign Application Priority Data

	Sep	o. 6, 1999	(JP) 11-251538
(5	51)	Int. Cl. ⁷	A01N 37/02 ; A01N 37/12;
			A61K 31/22; A61K 31/195; C07C 69/00
(5	52)	U.S. Cl.	514/546; 514/562; 514/604;
			514/618; 514/619; 560/138; 560/142

(56) References Cited

FOREIGN PATENT DOCUMENTS

EP	347168	12/1989
EP	0 519 354	12/1992
EP	539223	4/1993
EP	0 596 118	5/1994
WO	90/04409	5/1990

OTHER PUBLICATIONS

J. Cejkova et al., "Histochemical changes in the rabbit cornea and plasmin activity in the tear fluid during contact lens wear. Favourable influence of protease inhiitors (aprotinin, PC5, elastatinal)" Histochemistry, vol. 97, No. 1, 1992, pp. 69–76.

A. Spierer et al., "The effect of 2-mercaptoacetyl-L-phenylalanyl-L-leucine, a specific inhibitor of Pseudomonas aeruginos a elastase, on experimental Pseudomonas keratitis in rabbit eyes," Curr. Eye Res., vol. 3, No. 4, 1984, pp. 645–650.

Principles of Ambulatory Medicine, Fourth Edition. Barker et al, editors, pp. 943–952 and 1428–1431. Williams & Wilkins (1995).*

Webster's II New Riverside University Dictionary, p. 933, Houghton Mifflin Co. (1984).*

Gregory D. Sloop, et al., "Acute Inflammation of the Eyelid and Cornea in *Staphylococcus* Keratitis in the Rabbit," Invest. Ophthalmol. Vis. Sci., Feb. 1999, vol. 40, No. 2, pp. 385–391.

Jitka Čejková, "Histochemical Study of Leukocyte Elastase Activity in Alkali–Burned Rabbit Cornea," Opthalmic Research, 1997; 29, pp. 154–160.

O. Schmut, et al., "PMN-Elastase-Bestimmung in der Tränenflüssigkeit bei Ulcus corneae," Klin. Mbl. Augenheilk. 188, 1986, pp. 593–595.

Orhan Değer al., "Polymorphonuclear leukocyte elastase levels in patients with Behçet's disease," Clinica Chimica Acta, 236, 1995, pp. 129–134.

Nurettin Akyol, et al., "The importance of plasma polymorphonuclear (PMN) elastase determination in patients with uveitis," Acta Ophthalmol. Scandinavica, 1997, pp. 287–289.

Kiyohiro Tsutsui, et al., "Increased Plasma Granulocyte Elastase Levels in Behçet's Disease," Journal of Rheumatology, 1998; 25:2, pp. 326–328.

J.P. Barletta et al., "Inhibition of Pseudomonal Ulceration in Rabbit Corneas by a Synthetic Matrix Metalloproteinase Inhibitor," Invest. Ophthalmol. Vis. Sci., 1996, vol. 37, No. 1, pp. 20–28.

* cited by examiner

Primary Examiner—Richard L. Raymond
Assistant Examiner—Zachary C. Tucker
(74) Attorney, Agent, or Firm—Wenderoth, Lind & Ponack,
L.L.P.

(57) ABSTRACT

The present invention provides a prophylactic and therapeutic medicament for ophthalmic diseases, especially ophthalmic inflammatory diseases and corneal ulcer, comprising as an active ingredient a compound represented by the formula (I):

$$\begin{array}{c} CH_3 \\ CH_3 \\ C \\ CH_3 \end{array} \\ \begin{array}{c} CONHCH_2COOH \\ SO_2NH \\ \end{array}$$

(I)

or a pharmacologically acceptable salt or hydrate thereof.

27 Claims, 9 Drawing Sheets



Fig. 1




Fig. 2






Fig. 3





Fig. 4





DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

